enGene Holdings is a clinical-stage genetic medicine company developing therapies for serious diseases, including cancer, using a proprietary non-viral platform designed to deliver genetic medicines to mucosal tissues such as the bladder. The company's lead product candidate, detalimogene, targets BCG-unresponsive non-muscle invasive bladder cancer, and the platform can deliver varied biological cargos including DNA, antisense oligonucleotides, siRNA, mRNA, and gene-editing mechanisms to treat diseases of urogenital and gastrointestinal tissues. As a preclinical and early clinical-stage company with no approved products and no internal manufacturing capability, enGene relies on external partnerships and contract manufacturers while pursuing regulatory approval and clinical development of its proprietary genetic medicine platform.